Synergy Pharmaceuticals disclosure statement hearing reset to March 12

By Caroline Salls

Pittsburgh, Feb. 25 – Synergy Pharmaceuticals Inc. announced in a notice filed Monday with the U.S. Bankruptcy Court for the Southern District of New York that the hearing on approval of the disclosure statement for its Chapter 11 plan has been adjourned to March 12.

The hearing was previously scheduled for March 1.

Objections to the disclosure statement must be filed by 4 p.m. ET on March 4.

The notice did not give a reason for the adjournment.

Synergy is a New York-based biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies. The company filed bankruptcy on Dec. 12, 2018 under Chapter 11 case number 18-14010.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.